Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Philip Lenaerts has worked on the following 13 EPO patent applications which have been published in the last five years:

EP12717780

NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]BENZO-DIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH HETEROCYCLIC DERIVATIVES

IPC classification:
A61K 31/5513, C07D 487/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14719024

3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/437, A61P 35/00, C07D 471/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION REQUESTED
EP14715255

NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS

IPC classification:
A61K 31/517, A61P 35/00, C07D 403/12, C07D 403/14, C07D 405/14, C07D 409/14, C07D 413/14, C07D 471/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
PATENT GRANTED
EP14776635

NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

IPC classification:
A61K 31/505, C07D 471/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
PATENT GRANTED
EP14772372

NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

IPC classification:
A61K 31/506, A61P 35/00, C07D 471/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION IN PROGRESS
EP15713522

MACROCYLIC PYRIMIDINE DERIVATIVES

IPC classification:
A61K 31/505, A61P 35/00, C07D 471/22, C07D 498/22
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION REQUESTED
EP15712138

SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION REQUESTED
EP15713523

MACROCYLIC PYRIDINE DERIVATIVES

IPC classification:
A61K 31/505, A61P 35/00, C07D 471/22, C07D 498/22
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION REQUESTED
EP15713436

SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS

IPC classification:
A61K 31/519, A61K 35/00, C07D 487/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
EXAMINATION REQUESTED
EP15784360

NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS

IPC classification:
A61K 31/4155, A61P 35/00, C07D 401/14, C07D 403/04, C07D 403/14, C07D 407/14, C07D 413/14, C07D 417/14
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
Request for examination was made
EP15787516

NEW THIENOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS

IPC classification:
A61K 45/06, A61P 35/00, C07D 519/00
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
Request for examination was made
EP15784050

NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
Request for examination was made
EP15787932

NEW COMPOUNDS AS NIK INHIBITORS

IPC classification:
A61K 31/505, A61P 35/00, C07D 471/04
Applicant:
Janssen Pharmaceutica N.V.
Agent:
Philip Lenaerts, Janssen Pharmaceutica N.V.
Status:
Request for examination was made

Please Sign in to use this feature